Literature DB >> 17591911

Differential macular and peripheral expression of bestrophin in human eyes and its implication for best disease.

Robert F Mullins1, Markus H Kuehn, Elizabeth A Faidley, Nasreen A Syed, Edwin M Stone.   

Abstract

PURPOSE: Best disease, or vitelliform macular degeneration, is an autosomal dominant form of macular degeneration that is caused by mutations in the gene encoding bestrophin. On clinical examination, Best disease is characterized by an elevated lesion beneath the neurosensory retina, resembling an egg yolk. The lesions in Best disease are primarily restricted to the macula, a small region of the retina responsible for central vision. The nature of the vitelliform material and the reason the development of such lesions is usually restricted to the macula are two unsolved questions in the pathogenesis of this disorder.
METHODS: The expression of bestrophin protein and mRNA was evaluated by immunohistochemistry, Western blot, and quantitative PCR in a series of normal human eyes. The ultrastructure of the retinal pigment epithelium and the histopathology of two donors with clinically diagnosed Best disease were also examined.
RESULTS: An eye from a Best disease donor with a T6R mutation was found to have deposits containing lipid and glycoconjugates within the central retinal scar. These deposits may be remnants of the vitelliform lesion. Immunohistochemical localization of bestrophin in a series of 22 unaffected eyes revealed a pattern in which macular labeling was less robust than labeling outside the macula in most (18/22) cases. This pattern was confirmed using quantitative PCR and Western blotting.
CONCLUSIONS: Topographic differences in the levels of bestrophin protein may in part explain the propensity for the macula to develop lesions in Best disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591911     DOI: 10.1167/iovs.06-0868

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  55 in total

1.  Multimodal fundus imaging in Best vitelliform macular dystrophy.

Authors:  Daniela C Ferrara; Rogério A Costa; Stephen Tsang; Daniela Calucci; Rodrigo Jorge; K Bailey Freund
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-23       Impact factor: 3.117

Review 2.  Bestrophins and retinopathies.

Authors:  Qinghuan Xiao; H Criss Hartzell; Kuai Yu
Journal:  Pflugers Arch       Date:  2010-03-28       Impact factor: 3.657

3.  A facile method for immunofluorescence microscopy of highly autofluorescent human retinal sections using nanoparticles with large Stokes shifts.

Authors:  Howard R Petty; Victor M Elner; Takahiro Kawaji; Andrea Clark; Debra Thompson; Dong-Li Yang
Journal:  J Neurosci Methods       Date:  2010-07-07       Impact factor: 2.390

4.  Functional assessment of the fundus autofluorescence pattern in Best vitelliform macular dystrophy.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Claudia Del Turco; Giacinto Triolo; Francesco Bandello
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-21       Impact factor: 3.117

5.  Bestrophin detected in the basal membrane of the retinal epithelium and drusen of monkeys with drusenoid maculopathy.

Authors:  P Gouras; K Braun; L Ivert; M Neuringer; J A Mattison
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-07       Impact factor: 3.117

Review 6.  [Genetic diseases of the retinal pigment epithelium].

Authors:  M N Preising; B Lorenz
Journal:  Ophthalmologe       Date:  2009-04       Impact factor: 1.059

7.  Quantitative fundus autofluorescence in healthy eyes.

Authors:  Jonathan P Greenberg; Tobias Duncker; Russell L Woods; R Theodore Smith; Janet R Sparrow; François C Delori
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-08-21       Impact factor: 4.799

Review 8.  Bestrophin 1 and retinal disease.

Authors:  Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Prog Retin Eye Res       Date:  2017-01-30       Impact factor: 21.198

Review 9.  BEST1: the Best Target for Gene and Cell Therapies.

Authors:  Tingting Yang; Sally Justus; Yao Li; Stephen H Tsang
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

10.  Suppression of Ca2+ signaling in a mouse model of Best disease.

Authors:  Youwen Zhang; J Brett Stanton; Jiang Wu; Kuai Yu; H Criss Hartzell; Neal S Peachey; Lihua Y Marmorstein; Alan D Marmorstein
Journal:  Hum Mol Genet       Date:  2010-01-06       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.